**Introduction**

Hypertensive disorders (preeclampsia and gestational hypertension) affect 5-10% of pregnancies worldwide [1] and contribute significantly to the global burden of maternal and perinatal morbidity and mortality [2]. Studies have found that hypertensive pregnancy disorders associate with increased risk of short- and long-term maternal cardiovascular disease (CVD) [3-8]. We have recently found an increased risk for CVD associated with preeclampsia [9] and gestational hypertension [10], with the risk tending to be higher when the hypertensive pregnancy disorder occurred simultaneously with a small for gestational age (SGA) infant and/or preterm delivery. Whether pregnancy complications unmask an already existing CVD risk or whether the hypertensive pregnancy disorder is causally related to maternal risk of CVD remains uncertain. The first hypothesis is supported by the fact that established risk factors such age, smoking, elevated body mass index (BMI), low density lipoprotein (LDL) cholesterol, diabetes mellitus and a family history of coronary heart disease (CHD) are shared between hypertensive pregnancy disorders and CVD [11, 12], and that endothelial dysfunction is central to the development of both disorders [13, 14]. Alternatively, the proatherogenic stress of pregnancy could contribute to an arterial wall inflammation that is not resolved after delivery [15], and may lead to further increased risk of CVD. The two hypotheses are not mutually exclusive.

Although the overall CVD mortality rates have declined over the past decades in western countries [16], in the United States, mortality from coronary heart disease has plateaued among young women <55 years since the year 2000 [17] and in Norway, the overall falling incidence and recurrences of acute myocardial infarction over the past decades do not encompass younger women [18, 19].

In general, 80% of CVD development may be explained by established risk factors [20-22]. Existing knowledge of risk factors for future CVD is, however, limited in young women [23, 24]. While an association between hypertensive pregnancy disorders and later CVD has been repeatedly reported, the possible impact of established risk factors on this association is not known. An attenuation of risk estimates is observed when adjusting for established CVD risk factors, but hypertensive pregnancy disorders seem to remain persistent and significant predictors of later CVD [5, 6, 25-27]. The existing studies are limited by missing or inadequate data risk factors (e.g. lipids, blood pressure, height and weight) [5, 25-27], parity [6], gestational hypertension [6, 26] and by survival bias [6]. Furthermore, Cain et al. (2016) found higher risk of CVD after preeclampsia, but not after gestational hypertension, when accounting for established risk factors [5].

This study aimed to explore the extent to which established CVD risk factors explain the association between hypertensive pregnancy disorders in first pregnancy and subsequent risk of maternal CVD.

**Methods**

*Data material*

By use of the national identification number unique to each Norwegian resident, we linked data from the Medical Birth Registry of Norway (MBRN) [28] to Cohort of Norway (CONOR) health surveys [29], the Cardiovascular Disease in Norway 1994–2009 (CVDNOR) database [30,31], and the Norwegian Cause of Death Registry (1980-2009) [32]. Further linkages to Statistics Norway and the National Registry provided us with information on educational level and date of emigration. A detailed description of the registries can be found in supplemental material.

*Ethical considerations*

The study was approved by The Regional Committee for Medical and Health Research Ethics (2014/1047). All CONOR participants signed a written informed consent for research and linkage of health registries.

*Study population*

A total of 23,369 women (age 16-49 with parity ≤5) registered with a first delivery in the MBRN (1980 through 2003) subsequently participated in one or more regional CONOR surveys between 1994 and 2003. For women who had participated in more than one health survey after the first pregnancy (n=510), information from the last survey was used. Date of CONOR participation served as baseline for the follow-up evaluation of CVD events and we excluded women who were pregnant at that time (n=825). Women with a recorded diagnosis of CVD (ICD-9 codes 390-459; ICD–10 codes I00-I99, except 455/I84 (hemorrhoids)) in the MBRN/CVDNOR before baseline (CONOR) were excluded (n=469). Using information from the first pregnancy in the MBRN, we further excluded women with a delivery before 20 weeks of gestation and women with infants born with a weight-for-gestational age and sex z-score more extreme than -4/+4 (n=63); those with multiple-birth pregnancies (n=277); and missing information on SGA and/or preterm delivery (defined below) (n=1,415). In addition, we excluded women with missing CONOR information on age, blood pressure, total serum cholesterol (total- C), high-density lipoprotein cholesterol (HDL-C), triglycerides, daily smoking, BMI or a family history of MI (n=207). Lastly, women with missing information on education were excluded (n=38). The final cohort included 20,075 women (Supplementary Figure 1). Sensitivity analyses showed only minimal differences in characteristics of excluded women according to exposure status.

*Exposures*

The main exposures for the current study was gestational hypertension or preeclampsia in the first pregnancy. Gestational hypertension was defined as hypertension identified after 20 weeks of gestation (systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or an increase >15 mm Hg from blood pressure measured before gestational week 20). According to the definition in the MBRN, the preeclampsia diagnosis required the additional presence of proteinuria (≥0.3 g in 24 hour urine or ≥1 point increase on dip-stick), and also included eclampsia and the HELLP syndrome. SGA offspring was defined as fetal growth below the 10th percentile based on Norwegian sex-specific birthweight curves [33] and preterm delivery was defined as delivery before 37 weeks of gestation.

*Endpoints*

The primary endpoint was the first episode of CVD (ICD-9 codes 390-459; ICD-10 codes I00-I99; either non-fatal or fatal (except 455 and I84)) identified through CVDNOR or the Cause of Death Registry. The most frequent CVD diagnosis was hypertensive disease (ICD-9 401-405; ICD-10 I10-I15) (Supplementary Table 1), accounting for one third of the cases. Secondary endpoints included coronary heart disease (CHD) (ICD-9 410-414; ICD-10 I20-25), and the combined endpoint of acute myocardial infarction (AMI) or acute cerebral stroke. The endpoint AMI or acute cerebral stroke was defined as the first occurrence of hospitalization with AMI (ICD-9 410; ICD-10 I21-22) or death from CHD (ICD-9 410-414; ICD-10 I20-25), and hospitalization or death with acute cerebral stroke (ICD-9 43; ICD-10 I60-61, I63-64 (except I63.6)).

*Statistical analyses*

All potential CVD risk factors available were evaluated for statistical associations with the exposure (hypertensive disorders of pregnancy) and the outcomes (CVD). From the MBRN we used mother’s age at first delivery. From CONOR we first evaluated the following parameters separately: age at baseline (CONOR), blood pressure reading in the hypertensive range [hereafter referred to as hypertension [defined as systolic blood pressure ≥140 and/or diastolic blood pressure ≥90 mm Hg and/or use of antihypertensive drugs (yes or no)], diabetes mellitus (yes (type 1, type 2, unspecified) or no), daily smoking (yes or no), family history of MI before the age of 60 (yes or no), low HDL-C ( yes (≤1.3 mmol/L) or no)), total-C (mmol/L), triglycerides (mmol/L), glucose (mmol/L) alcohol consumption (never/seldom, monthly, weekly), vigorous physical activity (hours per week: none, less than 1, 1-2, 3 or more) and BMI (kg/m2) (model 1). Information on serum glucose, alcohol consumption and physical vigorous activity was missing for 13.1%, 4.7% and 8.7% of the women, respectively, and were therefore not included in the main analyses. Secondly, risk associations were explored using Cox proportional hazard regression and results were reported as hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). The proportional hazards assumption was checked by inspecting log-(log) survival plots for all relevant variables. Follow-up time was calculated as time from participation in CONOR until hospital admission, death, emigration or December 31, 2009 (whichever occurred first).

Hypertensive pregnancy disorders were stratified into gestational hypertension and preeclampsia and term and preterm deliveries to study potential subgroup differences. We also tested for significant interactions between hypertensive pregnancy disorders and each of the CVD risk factors. No interactions were significant and therefore not included in further analyses.

In additional analyses, we excluded women who had their first delivery within six months before CONOR and women who had a subsequent delivery within six months before or nine months after CONOR since these women may have risk factor alterations due to pregnancy itself. Further, we also included all established CVD risk factors in the fully adjusted model independent of missing values to study potential changes in estimates; women with missing values on one or more covariates were excluded from these analyses (complete case analysis).

The level of significance was defined as P <0.05 in all analyses. Stata 15 and ***R*** were used in the analyses.

*Risk prediction*

We investigated the potential value of including hypertensive pregnancy disorders in CVD risk prediction by comparing two models. Model 1 included age at baseline, age at first delivery, hypertension, diabetes mellitus, daily smoking, family history of MI before the age of 60, low HDL-C, total-C, triglycerides and BMI. Model 2 additionally included hypertensive pregnancy disorder. All continuous variables were mean centered to get a reasonable baseline level for estimation of baseline survival. The predicted 10-year risk was calculated for both model 1 and model 2 as

where is the predicted baseline survival at 10 years of follow-up, Z is the vector of covariates and β is the vector of regression coefficients.

The models` ability to distinguish between those who do and do not develop the disease of interest (discrimination) was evaluated with Harrell’s C-statistics [34] obtained using the STATA package somersd. Akaike information criterion (AIC) and Bayes information criterion (BIC) were reported as measures of improvement of model fit. Studies have shown that the C-statistic is insensitive in evaluating risk prediction models [35]. Thus, we calculated net reclassification improvement (NRI) and integrated discrimination improvement (IDI) using the “survIDINRI” package in ***R*** [36-38]. Only women with the possibility of at least 10 years follow-up for CVD were included in the risk prediction analyzes (n=12,389, events=688).

*Attributable risk*

The attributable fraction can be interpreted as the burden of CVD attributable to hypertensive pregnancy disorders. The attributable fraction was calculated by the STATA package *punafcc* and presented as percentages[39].

**Results**

*Characteristics of the study population*

Baseline demographic characteristics stratified by hypertensive pregnancy disorder are presented in Table 1. The mean (standard deviation (SD)) for the time between first delivery and participating in CONOR was 10.7 (5.5) years. Mean (SD) age of women at first delivery was 26.0 (4.6) years. A total of 1246 (6.2%) women were diagnosed with a hypertensive pregnancy disorder in their first pregnancy. Women with a hypertensive pregnancy disorder had a greater prevalence of preterm (P <0.001), SGA (P <0.001) and stillbirth deliveries (P =0.001) compared to women without a hypertensive pregnancy disorder. In the subsequent CONOR health survey, women with a hypertensive pregnancy disorder had higher prevalence of diabetes mellitus and systolic and diastolic blood pressure, BMI, total-C and triglycerides, but lower HDL-C, as well as less smoking and alcohol consumption compared to women with no hypertensive pregnancy disorder (all P <0.001).

Figure 1 presents age-adjusted HR`s for CVD events for each CVD risk factor examined. Vigorous physical activity reported at CONOR baseline was associated with a decreased risk of CVD (HR 0.8; 95% CI 0.7-0.9). All other factors analyzed predicted an increased risk of CVD; e.g. women with hypertension and women with BMI ≥30 had HR`s of 3.5 (95% CI 3.1-4.0) and 3.2 (2.7-3.7), respectively, for the risk of CVD.

*The importance of CVD risk factors in the association between hypertensive pregnancy disorder and later CVD*

Associations of hypertensive pregnancy disorder with subsequent maternal CVD are presented in Table 2. The median duration of follow-up from CONOR participation was 11.4 years (Q1-Q3: 8.7-13.6). In the unadjusted analyses, hypertensive pregnancy disorder in first pregnancy increased the risk of subsequent maternal CVD 2.3 times (95% CI 1.9-2.8). After adjustment for non-modifiable and modifiable risk factors, the HR was partially attenuated but remained an independent risk factor for maternal CVD (HR 1.5; 95% CI 1.2-1.8). Corresponding HR for the combined endpoint AMI/acute cerebral stroke was 1.8 (95 % CI 1.1-2.9) and for CHD it was 1.5 (95% CI 0.9-2.6). These associations were evident for both preeclampsia and gestational hypertension (Table 2). In analyses also adjusting for non-fasting serum glucose, vigorous physical activity and alcohol consumption, comparable results were found (data not shown).

Women with hypertensive pregnancy disorder combined with preterm delivery had increased risk of CVD relative to women without hypertensive pregnancy disorder and term delivery; HR 1.9 (95% CI 1.3-2.9) for hypertensive pregnancy disorder, HR 3.6 (95% CI 1.7-7.6) for gestational hypertension and HR 1.6 (95% CI 1.0-2.7) for preeclampsia (Supplementary Table 2).

In additional analyses where we excluded women with deliveries around CONOR participation (six months before - nine months after) no notable changes in risk estimates were found (data not shown).

*The value of including hypertensive pregnancy disorders in risk prediction*

Based on established CVD risk factors registered at baseline (CONOR) (model 1), women with a history of hypertensive pregnancy disorder had a significantly higher predicted 10-year mean absolute risk of CVD compared to women with no hypertensive pregnancy disorder (0.06% vs 0.04%, P < 0.001). The 10-year risk of CVD for women with a history of hypertensive pregnancy disorder was further increased when hypertensive pregnancy disorder was included in the 10-year risk prediction model (model 2); 0.09% vs. 0.04%, P <0.001 (data not shown).

Table 3 shows that the predictive value of the survival model increased from 0.69 to 0.70 when hypertensive pregnancy disorders was included. Both AIC and BIC decreased in model 2, indicating an improvement of model fit. NRI and IDI showed no significant improvement in the risk prediction model by including hypertensive pregnancy disorder in the model.

*Population attributable risk*

A total of 7.3% (95% CI 5.1-9.5) of the risk of CVD could be attributed to hypertensive pregnancy disorder that occurred an average of 21.9 years earlier. After adjustment for CVD risk factors, measured an average of 10.7 years after delivery, the attributable fraction decreased to 4.3 (95% CI 1.9-6.6) (data not shown).

**Discussion**

After accounting for a number of established modifiable and non-modifiable CVD risk factors assessed on average 10 years after pregnancy, a 50% increased risk of maternal CVD after hypertensive pregnancy disorder in the woman`s first pregnancy persisted. This suggests that the association between the disorders is a result of both shared CVD risk factors and pregnancy specific components.

*Hypertensive pregnancy disorder and risk of CVD*

This study identified a strong and persistent risk of CVD after hypertensive pregnancy disorders when accounting for established CVD risk factors. Similar associations were found for CHD and the combined endpoint AMI/stroke.

Only one other large cohort study [6] with access to data on blood measures (i.e. lipids) and physical examinations (i.e. blood pressure, height and weight (BMI)) have identified an impact of hypertensive pregnancy disorders on the risk of future hypertension and CVD after adjustment for such parameters, but with somewhat smaller risk estimates. Ray et al. 2005 found an increased risk of CVD subsequent to experiencing maternal placental syndrome after controlling for CVD risk factors measured after the index delivery [25]. Cain et al. 2016 found similar overall results, but the risk of CVD following gestational hypertension did not remain significant when accounting for risk factors [5]. This is in contrast to our study where an increased risk of future CVD was found for both preeclampsia and gestational hypertension after adjustment. Timpka et al. 2017 and Egeland et al. 2018 reported a higher risk of chronic hypertension after hypertensive pregnancy after accounting for several CVD risk factors [26, 27]. In the latter study, the association remained in a sensitivity analysis restricted to women with a normal pre-pregnancy BMI (kg/m2) [27].

This study contributes important knowledge by showing an independent association between hypertensive pregnancy disorders and subsequent CVD, after taking into account the effects of several established CVD risk factors. Vascular damage associated with hypertensive pregnancy disorders is suggested as a mechanism for increasing women’s susceptibility to CVD later in life [40]. A link between pregnancy-related complications and CVD risk is biologically plausible and supported by the profound effects of pregnancy on the maternal cardio-metabolic system [41]. Our uncovering of a dependent and independent risk factor component in the association between hypertensive pregnancy disorder and later CVD, is suggestive that the underlying aetiology probably is a combination of both shared predispositions (familial/genetic and lifestyle) and a direct causal connection between the consequences of hypertensive pregnancy disorders and CVD [14, 42].

*The value of including hypertensive pregnancy disorders in risk prediction*

The negligible improvement of the 10-year risk prediction model after including hypertensive pregnancy disorder as a variable may be partly explained by the relatively short follow-up time in this study and the women`s young age. Women in the age group included here have a low absolute risk of CVD and few women met the 5 or 10% criteria that are recommended for intervention for prevention of CVD. Lower thresholds for interventions in young women and men are recommended since CVD risk factors over many years may cause irreversible vascular damage [43]. A downside with the established risk prediction models is that new variables need to be strongly related to the outcome in order to show statistically significant improvement [44, 45]. NRI and IDI are widely used methods based on risk stratification, but the translation into clinical practice is questioned [46], and we found no improvement when incorporating hypertensive pregnancy disorder in the 10-year risk prediction model.

We have only identified one previous study who have investigated the predictive value of incorporating hypertensive pregnancy disorders into a CVD risk prediction model [47?], and similar to our study, they found now improvement in neither discrimination nor risk reclassification. This study was limited by self-reported information on hypertension in pregnancy, SBP and the use of predicted, rather than measured, total and HDL cholesterol levels.

Altogether, our findings substantiate larger studies with longer follow-up to determine whether hypertensive pregnancy disorders could be a valuable addition to maternal CVD prediction scores. Monitoring of women with hypertensive pregnancy disorders is needed as they are at higher risk for future CVD. These women should be considered for lifestyle rehabilitation aiming at reducing smoking and overweight and improving diet and physical activity, and, when indicated, targeted for pharmacological treatment of important mediators, such as hypertension and diabetes mellitus.

*Population attributable fraction*

About 4.3% of the cardiovascular events, occurring an average of 21.9 years after delivery, could be attributed to a history of hypertensive pregnancy disorder after adjusting for risk factors measured an average of 10.7 years after delivery. In contrast, a recent Norwegian study found that 25.3% of pharmacologically treated hypertension within 10 years of delivery was attributed to preeclampsia/gestational hypertension after adjusting for 10 important pre-pregnancy and 6-months post-partum covariates [27]. The sizable differences in the attributable fractions between the current and aforementioned study, likely relate to the length of follow-up and the differences in the outcomes assessed. Successful identification and treatment of hypertension, a major determinant of CVD and a key mediator between hypertensive pregnancy disorders and subsequent CVD, would be expected to result in a low attributable fraction percentage associated with hypertensive pregnancy disorders in the current study. Nonetheless, the current findings further support that a history of hypertensive pregnancy disorders could identify women at risk not identifiable through established CVD risk factors.

*Strengths and limitations*

The major strengths of our study are the large national cohort with follow-up of incident non-fatal and fatal CVD. We investigated women in a relatively homogeneous low-risk population with low loss to follow-up (<5%), and detailed information on a large number of shared risk factors for hypertensive pregnancy disorders and CVD was available. However, several limitations need to be addressed. Our data are based on a single measurement of risk factors after the woman’s first delivery, and cannot account for changes in risk factors over time. Information on diet, genetic, and other risk factors were not available. Residual confounding may also have occurred due to inappropriate or imprecise measurements of the CVD risk factors. The diagnostic validity for preeclampsia in the MBRN is high [47], but gestational hypertension may be less reliable due to underreporting of the less severe cases [48] and misdiagnosed chronic hypertension [49]. The positive predictive value for gestational hypertension is 68% [50]. Inclusions of deliveries from 1980-1993 gave up to 14 years without morbidity follow-up, but the number of CVD events before 1994 is expected to be very low due to the women`s young age. This limitation has been described in details in a previous publication [9].

*Conclusion*

The association between hypertensive pregnancy disorder and maternal CVD is partially explained by established CVD risk factors such as, smoking, elevated BMI, diabetes and dyslipidemia, but there remains an increased risk of CVD associated with hypertensive pregnancy disorder after taking these risk factors into account, pointing to a separate pregnancy specific contribution. Even among young women a healthy lifestyle plays an important role in prevention of CVD, and targeted follow-up programs should be initiated to assess prevention of CVD at an early stage.

**References**

1. American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-31.

2. Sibai BM. Hypertension in Pregnancy. Clin Obstet Gynecol 2016.

3. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974.

4. Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013;28:1-19.

5. Cain MA, Salemi JL, Tanner JP, Kirby RS, Salihu HM, Louis JM. Pregnancy as a window to future health: maternal placental syndromes and short-term cardiovascular outcomes. Am J Obstet Gynecol 2016;215:484 e1- e14.

6. Heida KY, Franx A, van Rijn BB, Eijkemans MJ, Boer JM, Verschuren MW, Oudijk MA, Bots ML, van der Schouw YT. Earlier Age of Onset of Chronic Hypertension and Type 2 Diabetes Mellitus After a Hypertensive Disorder of Pregnancy or Gestational Diabetes Mellitus. Hypertension 2015;66:1116-22.

7. Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A. All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease. Hypertension 2017;70:798-803.

8. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, Thilaganathan B, Boyd HA. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. Bmj-Brit Med J 2017;358.

9. Riise HK, Sulo G, Tell GS, Igland J, Nygard O, Vollset SE, Iversen AC, Austgulen R, Daltveit AK. Incident Coronary Heart Disease After Preeclampsia: Role of Reduced Fetal Growth, Preterm Delivery, and Parity. J Am Heart Assoc 2017;6.

10. Riise HKR, Sulo G, Tell GS, Igland J, Nygard O, Iversen AC, Daltveit AK. Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 Norwegian Women. J Am Heart Assoc 2018;7.

11. Egeland GM, Klungsoyr K, Oyen N, Tell GS, Naess O, Skjaerven R. Preconception Cardiovascular Risk Factor Differences Between Gestational Hypertension and Preeclampsia: Cohort Norway Study. Hypertension 2016;67:1173-80.

12. Berends AL, de Groot CJ, Sijbrands EJ, Sie MP, Benneheij SH, Pal R, Heydanus R, Oostra BA, van Duijn CM, Steegers EA. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension 2008;51:1034-41.

13. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis 2008;2:249-59.

14. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004;175:189-202.

15. Staff AC, Redman CW. IFPA Award in Placentology Lecture: preeclampsia, the decidual battleground and future maternal cardiovascular disease. Placenta 2014;35 Suppl:S26-31.

16. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 2015;372:1333-41.

17. Wilmot KA, O'Flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary Heart Disease Mortality Declines in the United States From 1979 Through 2011: Evidence for Stagnation in Young Adults, Especially Women. Circulation 2015;132:997-1002.

18. Sulo G, Igland J, Nygard O, Vollset SE, Ebbing M, Tell GS. Favourable trends in incidence of AMI in Norway during 2001-2009 do not include younger adults: a CVDNOR project. Eur J Prev Cardiol 2014;21:1358-64.

19. Sulo G, Nygard O, Vollset SE, Igland J, Egeland GM, Ebbing M, Tell GS. Trends in acute myocardial infarction hospitalization rates in Norway during 1994-2009; a CVDNOR project. European Heart Journal 2013;34:467-.

20. Mannsverk J, Wilsgaard T, Mathiesen EB, Lochen ML, Rasmussen K, Thelle DS, Njolstad I, Hopstock LA, Bonaa KH. Trends in Modifiable Risk Factors Are Associated With Declining Incidence of Hospitalized and Nonhospitalized Acute Coronary Heart Disease in a Population. Circulation 2016;133:74-81.

21. O'Flaherty M, Buchan I, Capewell S. Contributions of treatment and lifestyle to declining CVD mortality: why have CVD mortality rates declined so much since the 1960s? Heart. 2013;99:159-62.

22. Tunstall-Pedoe H. The decline in coronary heart disease; did it fall or was it pushed? BMJ 2012;344:d7809.

23. Robbins SL, Kumar V, Cotran RS. Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2010. xiv, 1450 p. p.

24. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016;37:3232-45.

25. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797-803.

26. Timpka S, Stuart JJ, Tanz LJ, Rimm EB, Franks PW, Rich-Edwards JW. Lifestyle in Progression From Hypertensive Disorders of Pregnancy to Chronic Hypertension in Nurses' Health Study II: Observational Cohort Study. Obstetrical & Gynecological Survey 2017;72:701-3.

27. Egeland GM, Skurtveit S, Staff AC, Eide GE, Daltveit AK, Klungsoyr K, Trogstad L, Magnus PM, Brantsaeter AL, Haugen M. Pregnancy-Related Risk Factors Are Associated With a Significant Burden of Treated Hypertension Within 10 Years of Delivery: Findings From a Population-Based Norwegian Cohort. J Am Heart Assoc 2018;7.

28. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand 2000;79:435-9.

29. Naess O, Sogaard AJ, Arnesen E, Beckstrom AC, Bjertness E, Engeland A, Hjort PF, Holmen J, Magnus P, Njolstad I, Tell GS, Vatten L, Vollset SE, Aamodt G. Cohort profile: cohort of Norway (CONOR). Int J Epidemiol 2008;37:481-5.

30. Igland J, Tell GS, Ebbing M, Nygaard OK, Vollset SE, D. T, . CVDNOR data and quality report: the CVDNOR project: cardiovascular disease in Norway 1994-2009. Description of data and data quality. Norway: University of Bergen, 2013.

31. Sulo G, Igland J, Vollset SE, Nygaard OK, Oyen N, Tell GS. Cardiovascular disease and diabetes mellitus in Norway during 1994-2009 CVDNOR – a nationwide research project. Norwegian J Epidemiology 2013;23:101-7.

32. Pedersen AG, Ellingsen CL. Data quality in the Causes of Death Registry. Tidsskr Nor Laegeforen 2015;135:768-70.

33. Skjaerven R, Gjessing HK, Bakketeig LS. Birthweight by gestational age in Norway. Acta Obstet Gynecol Scand 2000;79:440-9.

34. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.

35. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Annals of Internal Medicine 2006;145:21-9.

36. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.

37. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.

38. Uno H, Tian L, Cai TX, Kohane IS, Wei LJ. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med 2013;32:2430-42.

39. Eide GE, Heuch I. Attributable fractions: fundamental concepts and their visualization. Stat Methods Med Res 2001;10:159-93.

40. Enkhmaa D, Wall D, Mehta PK, Stuart JJ, Rich-Edwards JW, Merz CN, Shufelt C. Preeclampsia and Vascular Function: A Window to Future Cardiovascular Disease Risk. J Womens Health (Larchmt) 2016;25:284-91.

41. Peters SAE, Regitz-Zagrosek V. Pregnancy and risk of cardiovascular disease: is the relationship due to childbearing or childrearing? European Heart Journal 2017;38:1448-50.

42. Staff AC, Dechend R, Redman CW. Review: Preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses. Placenta 2013;34 Suppl:S73-8.

43. Selmer R, Igland J, Ariansen I, Tverdal A, Njolstad I, Furu K, Tell GS, Klemsdal TO. NORRISK 2: A Norwegian risk model for acute cerebral stroke and myocardial infarction. Eur J Prev Cardiol 2017;24:773-82.

44. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35.

45. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882-90.

46. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009;150:795-802.

47. Thomsen LC, Klungsoyr K, Roten LT, Tappert C, Araya E, Baerheim G, Tollaksen K, Fenstad MH, Macsali F, Austgulen R, Bjorge L. Validity of the diagnosis of pre-eclampsia in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand 2013;92:943-50.

48. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009;53:944-51.

49. Dayan N, Lanes A, Walker MC, Spitzer KA, Laskin CA. Effect of chronic hypertension on assisted pregnancy outcomes: a population-based study in Ontario, Canada. Fertil Steril 2016;105:1003-9.

50. Moth FN, Sebastian TR, Horn J, Rich-Edwards J, Romundstad PR, Asvold BO. Validity of a selection of pregnancy complications in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand 2016;95:519-27.

**Figure title and legends**

Figure 1

Title: Lifestyle and cardiovascular risk factors and their associations with subsequent maternal cardiovascular disease (I00-99) among 20,075 young Norwegian women

Legend:CONOR indicates Cohort of Norway 1994-2003; HR, age-adjusted hazard ratio (all variables except mother`s age at first delivery are adjusted for age at participation in CONOR); CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hypertension defined as SBP ≥140 or DPB ≥90 or currently on antihypertensive drugs; MI, myocardial infarction; Glucose; Diabetes, type 1, type 2 or unspecified diagnosed before baseline: HDL-C, low high-density lipoprotein cholesterol; Daily smoking, daily smoker versus not daily smoker; Alcohol consumption, drinking weekly compared to never/seldom; BMI, body mass index (categorical(<25 reference)); Vigorous physical activity, less than 1 hour a week versus 1 or more hours a week

Supplementary Figure 1

Title: Flow chart of the study population of 20,075 Norwegian women.

Legend: CVD indicates cardiocascular disease; CONOR, Cohort of Norway;SGA, small for gestational age; preterm delivery, <37 weeks of gestation; BMI, body mass index; MI, myocardial infarction; HDL-C, high-density lipoprotein cholesterol.

Hypertensive pregnancy disorders increase the risk of maternal cardiovascular disease after adjustment for cardiovascular risk factors

* Tables

**Table 1 Characteristics of 20,075 Norwegian women with or without a hypertensive pregnancy disorder who subsequently participated in Cohort of Norway (CONOR, 1993-2004)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | | No hypertensive pregnancy disorder (18,829 (93.8 %)) | Hypertensive pregnancy disorder (1246 (6.2 %)) |
| Mother`s age at first delivery, mean (SD) | | 26.0 (4.6) | 26.2 (4.8) |
| Infant characteristics | |  |  |
|  | Preterm delivery, n (%) | 902 (4.8) | 196 (15.7)\*\* |
|  | Small for gestational age, n (%) | 2500 (13.3) | 316 (25.4)\*\* |
|  | Stillbirth, n (%) | 123 (0.7) | 18 (1.4)\* |
| Parity at baseline, mean (SD) | | 2.0 (0.8) | 2.0 (0.8)\* |
| Mother`s age at CONOR, mean (SD) | | 37.2 (6.5) | 37.1 (6.7)\* |
| Education level | |  | \* |
|  | Basic education, n (%) | 5824 (31.0) | 424 (34.1) |
|  | Secondary education, n (%) | 4900 (26.0) | 363 (29.1) |
|  | Tertiary education, n (%) | 8105 (43.0) | 459 (36.8) |
| Marital status | |  |  |
|  | Married/cohabitants, n (%) | 14,621 (77.7) | 993 (79.7) |
|  | Other, n (%) | 4208 (22.3) | 253 (20.3) |
| Systolic blood pressure, mean (SD) | | 118.8 (12.6) | 127.8 (15.1)\*\* |
| Diastolic blood pressure, mean (SD) | | 70.1 (9.3) | 75.9 (10.2)\*\* |
| Hypertension § | |  | \*\* |
|  | No, n (%) | 17,391 (92.4) | 936 (75.1) |
|  | Yes, n (%) | 1438 (7.6) | 310 (24.9) |
| Current use of antihypertensive drugs, n (%) | | 221 (1.2) | 75 (6.02)\*\* |
| Family history of MI | |  | \*\* |
|  | One family member, n (%) | 2294 (12.2) | 174 (14.0) |
|  | Two or more family members, n (%) | 148 (0.8) | 13 (1.0) |
| Glucose, n (%) | | 5.0 (0.9) | 5.2 (1.5)\*\* |
| Diabetes mellitus †, n (%) | | 160 (0.9) | 30 (2.4)\*\* |
| Elevated total cholesterol (> 5.0 mmol/L), n (%) | | 9839 (53.3) | 719 (57.7)\*\* |
| Low HDL (< 1.3 mmol/L), n (%) | | 6688 (35.5) | 535 (43.0)\*\* |
| Elevated triglycerides (≥ 1.7 mmol/L) ‡, n (%) | | 3165 (16.8) | 329 (26.4)\*\* |
| Current daily smoking | |  | \*\* |
|  | No, n (%) | 12,909 (68.6) | 942 (75.6) |
|  | Yes, n (%) | 5920 (31.4) | 304 (24.4) |
| Alcohol | |  | \*\* |
|  | Never/seldom, n (%) | 5916 (31.4) | 452 (36.3) |
|  | Monthly, n (%) | 7549 (40.1) | 526 (42.2) |
|  | Weekly, n (%) | 4479 23.8) | 209 (16.8) |
|  | Missing, n (%) | 885 (4.7) | 59 (4.7) |
| BMI units (kg/m2) | |  | \*\* |
|  | < 25.0, n (%) | 11,671 (62.0) | 515 (41.3) |
|  | 25.0-29.9, n (%) | 5282 (28.1) | 441 (35.4) |
|  | ≥30.0, n (%) | 1876 (10.0) | 290 (23.3) |
| Vigorous physical activity | |  |  |
|  | Less than 1 hour peer week, n (%) | 10,821 (57.5) | 711 (57.1) |
|  | 1 or more hours per week, n (%) | 6390 (33.9) | 415 (33.3) |
|  | Missing, n (%) | 1618 (8.6) | 120 (9.6) |

Hypertensive pregnancy disorders indicate gestational hypertension or preeclampsia; preterm delivery, <37 weeks of gestation; small for gestational age, <10th percentile; stillbirth, ≥20 weeks of gestation.

\*indicates P <0.05 and \*\*indicates P <0.001 for comparisons of women with and without hypertensive pregnancy disorder. Chi-square test for categorical data and t-test for continuous data.

† Diabetes mellitus (defined as type 1, type 2, or unspecified) diagnosed before the first pregnancy and/or in CONOR.

‡ A non-fasting blood sample was collected for serum lipid and glucose analyses.

§ Hypertension defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 or use of antihypertensive drugs.

**Table 2 Risk of cardiovascular disease according to hypertensive disorder (HPD) in first pregnancy (1980-2009) among 20,075 Norwegian women**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | No./Events | Unadjusted  HR (95% CI) | Model A  HR (95% CI)\* | Model B  HR (95% CI)† |
| Total CVD | |  |  |  |  |
| No HPD‡ | | 18,829/840 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| HPD | | 1246/125 | 2.3 (1.9-2.8) | 2.3 (1.9-2.7) | 1.5 (1.2-1.8) |
|  | Preeclampsia | 884/83 | 2.1 (1.7-2.7) | 2.2 (1.7-2.7) | 1.5 (1.2-1.9) |
|  | Gestational hypertension | 362/42 | 2.7 (2.0-3.6) | 2.5 (1.8-3.4) | 1.5 (1.1-2.0) |
|  |  |  |  |  |  |
| AMI/acute cerebral stroke | |  |  |  |  |
| No HPD ‡ | | 18,829/128 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| HPD | | 1246/19 | 2.2 (1.4-3.6) | 2.2 (1.4-3.6) | 1.8 (1.1-2.9) |
|  | Preeclampsia | 884/13 | 2.2 (1.2-3.8) | 2.2 (1.3-3.9) | 1.8 (1.0-3.3) |
|  | Gestational hypertension | 362/6 | 2.4 (1.1-5.5) | 2.2 (1.0-5.1) | 1.8 (0.8-4.1) |
|  |  |  |  |  |  |
| CHD | |  |  |  |  |
| No HPD ‡ | | 18,829/116 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| HPD | | 1246/16 | 2.2 (1.2-3.5) | 1.9 (1.1-3.2) | 1.5 (0.9-2.6) |
|  | Preeclampsia | 884/10 | 1.8 (1.0-3.5) | 1.8 (0.9-3.4) | 1.4 (0.7-2.7) |
|  | Gestational hypertension | 362/6 | 2.7 (1.2-6.1) | 2.2 (1.0-5.1) | 1.7 (0.7-4.0) |

CVD indicates cardiovascular disease; AMI, acute myocardial infarction; CHD, coronary heart disease; HPD, hypertensive pregnancy disorder; HR, hazard ratio; CI, confidence interval.

\* Adjusted for non-modifiable risk factors: age at baseline (yrs.), age at first delivery (yrs.), education (primary, high school/vocational, any college/university) and a family history of MI prior to age 60.

† Adjusted for non-modifiable and modifiable risk factors: age at baseline (yrs.), age at first delivery (yrs.), education (primary, high school/vocational, any college/university), hypertension (systolic blood pressure ≥140 or diastolic blood pressure ≥90 or currently on antihypertensive drugs), total serum cholesterol (mmol/L), low high-density lipoprotein cholesterol (<1.3 mmol/L), triglycerides (mmol/L), daily smoking, body mass index (kg/m2), diabetes mellitus and family history of MI prior to age 60.

‡ No preeclampsia or gestational hypertension in first pregnancy.

**Table 3 Comparison of two different risk prediction models for 10-year risk of cardiovascular disease**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Total CVD | C Statistics\* | 95% CI | P -value | AIC | BIC | NRI (p-value)§ | IDI (p-value)§ |
| Prediction model 1† | 0.69 | 0.67-0.72 | < 0.001 | 12445.68 | 12527.35 |  |  |
| Prediction model 2‡ | 0.70 | 0.68-0.72 | < 0.001 | 12436.25 | 12525.35 | 0.055 (0.066) | 0.001 (0.133) |

CVD indicates cardiovascular disease; HR, hazard ratio; CI, confidence interval; AIC, Akaike information criteria: BIC, Bayesian information criteria; NRI, net reclassification improvement; IDI, integrated discrimination improvement.

\*The Harrell`s C statistics were obtained by use of the “somersd” package in STATA 15. Only women with the possibility of at least 10 years of follow-up were included (n=12,389).

†Prediction model 1 includes age at baseline (yrs.), age at first delivery (yrs.), educational level (primary, high school/vocational, any college/university), hypertension (systolic blood pressure ≥140 or diastolic blood pressure ≥90 or currently on antihypertensive drugs), total serum cholesterol (mmol/L), low high-density lipoprotein cholesterol (<1.3 mmol/L), triglycerides (mmol/L), daily smoking, body mass index (kg/m2), diabetes mellitus and family history of MI prior to age 60.

‡ Prediction model 2 includes the variables in prediction model 1 in addition to hypertensive pregnancy disorder (preeclampsia, gestational hypertension).

§Result of continuous NRI and IDI using the “survIDINRI” package in ***R***.